Join us at EACR-AACR-IACR Basic and Translational Research Conference

Dublin, Ireland

Share

Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.


Introduction

The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).

Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.


Background

Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.

Target Audience

The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.


Introduction

The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).

Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.


Background

Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.

Target Audience

The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.


Introduction

The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).

Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.


Background

Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.

Target Audience

The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.

MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.


Introduction

The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).

Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.


Background

Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.

Target Audience

The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.

Topics to be covered:

Immunotherapy / Immuno-Oncology

Cell-Based Therapies

Novel Targets / Undruggable Targets

Drug Combinations

Drug Resistance

The Precancer Genome

Liquid Biopsies

Preclinical Models

Tumour Microenvironment

Epigenetics

EACRAACRIACR2024

Science To Clinic

Rsearch Innovation

Events

EARC

Share this article :

Share

More Events

Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024

Mar 18, 2024

Join MGI at Spatial Biology UK 2024

Discover Genomic Innovations with MGI at Spatial Biology UK 2024! Join us on March 18th-19th at booth 15 at Novotel London West. Don't miss out!

Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January

Jan 24, 2024

Join us at The Festival of Genomics & Biodata in January

Join us at booth 98 with MGI Tech during The Festival of Genomics & Biodata on January 24th-25th, 2024, at ExCeL in London.

Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris
Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris
Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris
Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris

Jan 9, 2024

Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris

Join us at booth 19 with MGI Tech during the Assises de Génétique Humaine et Médicale from January 9 to January 12, 2024 at Palais de Congrès in Paris.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.